A detailed history of Royal Bank Of Canada transactions in Grifols Sa stock. As of the latest transaction made, Royal Bank Of Canada holds 353,641 shares of GRFS stock, worth $2.9 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
353,641
Previous 252,406 40.11%
Holding current value
$2.9 Million
Previous $1.69 Million 32.09%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$6.27 - $7.7 $634,743 - $779,509
101,235 Added 40.11%
353,641 $2.23 Million
Q1 2024

May 15, 2024

SELL
$5.47 - $11.38 $21,584 - $44,905
-3,946 Reduced 1.54%
252,406 $1.69 Million
Q4 2023

Feb 14, 2024

BUY
$7.71 - $11.56 $46,784 - $70,146
6,068 Added 2.42%
256,352 $2.96 Million
Q3 2023

Nov 14, 2023

SELL
$8.91 - $10.91 $98,357 - $120,435
-11,039 Reduced 4.22%
250,284 $2.29 Million
Q2 2023

Aug 14, 2023

SELL
$7.14 - $9.29 $8,082 - $10,516
-1,132 Reduced 0.43%
261,323 $2.39 Million
Q1 2023

May 15, 2023

SELL
$6.65 - $10.69 $29,000 - $46,619
-4,361 Reduced 1.63%
262,455 $1.93 Million
Q4 2022

Feb 14, 2023

BUY
$5.96 - $8.53 $84,506 - $120,946
14,179 Added 5.61%
266,816 $2.27 Million
Q3 2022

Nov 14, 2022

SELL
$5.95 - $14.3 $220,489 - $529,915
-37,057 Reduced 12.79%
252,637 $1.56 Million
Q2 2022

Aug 15, 2022

SELL
$10.6 - $13.28 $41,870 - $52,456
-3,950 Reduced 1.35%
289,694 $3.44 Million
Q1 2022

May 16, 2022

BUY
$10.37 - $12.73 $477,621 - $586,318
46,058 Added 18.6%
293,644 $3.43 Million
Q4 2021

Feb 14, 2022

SELL
$10.21 - $15.27 $43,943 - $65,722
-4,304 Reduced 1.71%
247,586 $2.78 Million
Q3 2021

Nov 15, 2021

SELL
$14.07 - $17.3 $1.22 Million - $1.5 Million
-86,963 Reduced 25.66%
251,890 $3.68 Million
Q2 2021

Aug 16, 2021

BUY
$16.62 - $18.94 $5.63 Million - $6.42 Million
338,853 New
338,853 $5.88 Million

Others Institutions Holding GRFS

About Grifols SA


  • Ticker GRFS
  • Exchange OTC
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 678,910,976
  • Market Cap $5.57B
  • Description
  • Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others divisions. The Bioscience division researches, develops, produces, and markets plasma-derived medicines and other innovative solut...
More about GRFS
Track This Portfolio

Track Royal Bank Of Canada Portfolio

Follow Royal Bank Of Canada and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

News

Stay updated on Royal Bank Of Canada with notifications on news.